Nexsen Accelerates US Entry for Rapid GBS Test with FDA Pre-Submission and Leadership Boost

Nexsen Limited ( (AU:NXN) ) has provided an announcement.

Nexsen has lodged a pre-submission with the US Food and Drug Administration for its rapid Group B Streptococcus point-of-care diagnostic under the 510(k) pathway, formally commencing US regulatory engagement ahead of schedule in the world’s largest maternal health market. The company expects written FDA feedback within about 70 days, which will guide the final clinical validation program and a subsequent 510(k) submission, potentially enabling a faster, less costly route to US market clearance, earlier revenue generation and strengthened competitive positioning in rapid maternal diagnostics. To support its transition from development to commercial operations and international rollout, Nexsen has appointed experienced finance executive Richard Jarvis as Chief Financial Officer on a fractional basis, reinforcing its capital markets and commercial readiness, while the recognition of Chief Innovation Officer Professor Vipul Bansal as an RMIT Distinguished Professor further underpins the scientific credibility and innovation depth behind Nexsen’s diagnostic platform and long-term growth strategy.

More about Nexsen Limited

Nexsen Limited (ASX:NXN) is a diagnostics-focused medical technology company developing rapid point-of-care testing solutions, with a current emphasis on its Group B Streptococcus (GBS) rapid sensor for maternal healthcare. The company aims to address critical clinical needs by delivering lab-grade diagnostic accuracy in minutes and is positioning its platform for international expansion, particularly in large markets such as the United States, while building internal capabilities in finance, commercial readiness and scientific innovation.

Average Trading Volume: 540,369

Find detailed analytics on NXN stock on TipRanks’ Stock Analysis page.